Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
denileukin diftitox + pegylated interferon alfa-2a
- Development stage
- Unknown
- Lead developer
- Citius Pharmaceuticals
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Denileukin diftitox + pegylated interferon alfa-2a is an investigational combination therapy studied primarily in the context of cancer immunotherapy, including ovarian cancer and cutaneous T-cell lymphoma. Denileukin diftitox is a recombinant fusion protein composed of interleukin-2 (IL-2) fused to diphtheria toxin, which selectively targets and kills cells expressing the high-affinity IL-2 receptor (CD25), such as malignant T cells and regulatory T cells (Tregs). Pegylated interferon alfa-2a is a modified form of interferon alpha with polyethylene glycol attached to increase its half-life; it acts as an immunomodulatory cytokine that enhances antitumor immune responses. The combination aims to deplete immunosuppressive Tregs via denileukin diftitox while boosting tumor-specific immunity through pegylated interferon alfa-2a, potentially overcoming resistance seen with monotherapy. Clinical studies have shown that this combination can produce immunologic and clinical benefits in some patients who did not respond to denileukin diftitox alone[1].
- Brand names
- PegasysOntak
- Other names
- Pegylated interferon alfa-2aPeg-IFN-alpha-2aPeg-IFN-alpha2aPeg-IFN-alpha 2aDenileukin Diftitox/SC Pegylated IFNα-2a
02
Targets
EEF2 (Eukaryotic elongation factor 2)IL2RA (Interleukin-2 receptor alpha subunit)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on denileukin diftitox + pegylated interferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on denileukin diftitox + pegylated interferon alfa-2a.